Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 4Genitourinary 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Other solid neoplasm 1Breast 1

Conditions

Prostatic Neoplasms 1Fallopian Tube Mucinous Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 44Specimen Handling 38enzalutamide 30Nivolumab 30pembrolizumab 28Docetaxel 23Gemcitabine 22apalutamide 20Prednisone 20Biopsy 20Abiraterone Acetate 18Androgen Antagonists 17cabozantinib 14darolutamide 13abiraterone 13Radiotherapy 13Cisplatin 12enfortumab vedotin 11Radiation 11Ipilimumab 11Pluvicto 10erdafitinib 9belzutifan 9atezolizumab 9X-Rays 9Radiosurgery 9Mitomycin 9olaparib 8cabazitaxel 8Standard of Care 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
cediranib × Genitourinary × 30 days × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

NCT02893917 2026-05-28

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
90 enrolled 19 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡